Research towards presence of Antibodies against European Bat Lyssavirus (EBLV) after immunization with Rabipur®
Completed
- Conditions
- rabies10047438
- Registration Number
- NL-OMON37212
- Lead Sponsor
- eids Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion Criteria
Age between 18 and 65 year
Healthy
Exclusion Criteria
A know or suspected allergy towards one of the components of the vaccine, i.e. chicken protein, polygeline, neomycin, chlorotetracyclin and amfotericine B.
History of serious allergic reactions
Use of medication to suppress immune response
A chronic disease that affects the immune system, systemic diseases such as SLE, ANCA associated vasculitis
Pregnancy or actual child wish (upon inquiry at the time of screening)
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary goal is to obtain PBMC*s of Rabipur® vaccinated individuals.</p><br>
- Secondary Outcome Measures
Name Time Method <p>demonstrate antibodies that are able to bind other lyssavirus genotypes, in<br /><br>particular EBLV.</p><br>